SWISS pharmaceutical giant
Novartis has announced the
success of clinical trials published
in the New England Journal of
Medicine demonstrating that one of
its two new antimalarial candidates
cleared the parasite rapidly in
plasmodium falciparum and
plasmodium vivax uncomplicated
malaria patients.
Novartis has a third candidate
with preventative potential but
not as developed as KAE609 or
KAF156 which are new classes of
anti-malarial compounds that treat
malaria in different ways from
current therapies, important to
combat emerging drug resistance.The above article was sent to subscribers in Pharmacy Daily's issue from 01 Aug 14 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 01 Aug 14
RESPONDING to the findings from the Royal Commission into Aged Care Quality and Safety, a recent government initiative aims to improve medication management in residential aged care facilities by introducing on-site pharmacists.
RESEARCHERS at Charles Darwin University (CDU) are advancing a novel drug delivery system that could potentially eliminate the need for injections to treat various chronic diseases.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.